Haisen Pharmaceutical Co., Ltd.

Announcement on the implementation of the 2025 annual equity distribution.

Announcement on the Resignation of the Chairman and the Election of a New Chairman, Representative for Company Affairs, Change of Legal Representative, and Supplementary Election of Members of the Board's Strategy and Sustainable Development Committee

Announcement on the Retirement of the Financial Officer and Appointment of a New Financial Officer

Legal Opinion from Beijing Deheng (Hangzhou) Law Firm on the 2025 Annual Shareholders' Meeting of Zhejiang Haisen Pharmaceutical Co., Ltd.

Resolution Announcement of the 2025 Annual Shareholders' Meeting

Resolution of the 20th Meeting of the 3rd Board of Directors

Quarterly Report for Q1 2026

Pre-disclosure Announcement on the Reduction of Shares by Shareholders Holding More than 5%

CITIC Securities Co., Ltd. on the verification opinions regarding the listing and circulation of shares issued prior to the initial public offering of Zhejiang Haishen Pharmaceutical Co., Ltd.

Announcement on the lifting of restrictions on shares issued prior to the initial public offering and their listing and circulation

Sponsorship Work Report for Zhejiang Haishen Pharmaceutical Co., Ltd. for the Year 2025 by CITIC Securities Co., Ltd.

On-site Inspection Results and Matters for Attention for Continuous Supervision Work of Zhejiang Haishen Pharmaceutical Co., Ltd. for the Year 2025 by CITIC Securities Co., Ltd.

Summary Report on Continuous Supervision of the Initial Public Offering and Listing of Zhejiang Haishen Pharmaceutical Co., Ltd. by CITIC Securities Co., Ltd.

Regular On-site Inspection Report on Zhejiang Haishen Pharmaceutical Co., Ltd. for the Year 2025 by CITIC Securities Co., Ltd.

Announcement on Holding the 2025 Online Performance Presentation

CITIC Securities Co., Ltd. Special Verification Opinion on Zhejiang Haisen Pharmaceutical Co., Ltd.'s Deposit and Use of Raised Funds in 2025

Announcement on the Proposed Re-appointment of Accounting Firm

2025 Annual Financial Settlement Report

2025 Annual Report of the Board of Directors

2025 Annual Report on the Performance of Duties by the Board of Directors' Audit Committee

Announcement on the Confirmation of Company Directors' and Senior Management's 2025 Annual Compensation and the 2026 Compensation Plan

2025 Annual Independent Director Performance Report (Zheng Gang)

2025 Annual Independent Director Performance Report (Dai Wentao)

2025 Annual Independent Director Performance Report (Fang Guirong)

CITIC Securities Co., Ltd. Verification Opinion on Zhejiang Haisen Pharmaceutical Co., Ltd.'s 2025 Annual Internal Control Evaluation Report

2025 Annual Internal Control Audit Report

2025 Annual Internal Control Evaluation Report

Directors and Senior Management Compensation Management System

Special Report on the Deposit and Use of Raised Funds in 2025

Notice of Convening the 2025 Annual General Meeting of Shareholders

Resolutions of the Nineteenth Meeting of the Third Board of Directors

Announcement on the 2025 Annual Profit Distribution Plan

Assurance Report on the Special Report on the Deposit and Use of Raised Funds

2025 Annual Assessment Report on the Performance of Duties by the Accounting Firm

2025 Annual Report of the Audit Committee on the Performance of Supervision Duties by the Accounting Firm

Special Review Opinion on Non-Operating Fund Occupancy and Other Related Fund Transactions

Summary Table of Non-Operating Fund Occupancy and Other Related Fund Transactions in 2025

Special Opinion on the Independence of Independent Directors in 2025

2025 Annual Audit Report

2025 Annual Report

Zhejiang Haisen Pharmaceutical Co., Ltd. 2025 Annual Report Summary

This report summarizes Zhejiang Haisen Pharmaceutical's 2025 performance. The company achieved operating revenue of 532,259,379.46 yuan and net profit attributable to shareholders of 135,879,665.78 yuan. Key decisions include a dividend distribution plan of 1.16 yuan per 10 shares and the approval of a new factory project. The company also advanced its stock incentive plan.

CITIC Securities Co., Ltd. Verification Opinion on Zhejiang Haisen Pharmaceutical Co., Ltd.'s Use of Partially Idle Raised Funds and Idle Own Funds for Cash Management

Announcement on Cash Management of Partially Idle Raised Funds and Own Funds

Zhejiang Hysen Pharmaceutical Co., Ltd. announces its plan to manage partially idle raised funds and own funds through cash management products. The company will invest up to RMB 300 million in raised funds and RMB 400 million in own funds. The purpose is to increase fund utilization efficiency and returns. The investment will focus on low-risk, high-liquidity products, ensuring no impact on fundraising projects.